HER2-positive breast cancer: current and future treatment strategies.
about
Identifying HER2 inhibitors from natural products databaseUnderstanding Drug Resistance in Breast Cancer with Mathematical OncologyLiver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism.The role of HER2 in cancer therapy and targeted drug deliveryA human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.Targeted treatment of advanced and metastaticbreast cancer with lapatinib.Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cellsPrognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer.A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report.Current status of antivascular therapy and targeted treatment in the clinic.Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells.Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaHER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor.Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer.Personalized medicine policy challenges: measuring clinical utility at point of care.Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer.Involvement of Numb-mediated HIF-1α inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells.Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients.Inhibition of ErbB-2 induces TFF3 downregulation in breast cancer cell lines.Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients.In vivo near-infrared imaging of ErbB2 expressing breast tumors with dual-axes confocal endomicroscopy using a targeted peptide.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Nanomaterials as nanocarriers: a critical assessment why these are multi-chore vanquisher in breast cancer treatment.Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe.Ultrasound-Activated Piezoelectric Nanoparticles Inhibit Proliferation of Breast Cancer Cells.Expression of Minichromosome Maintenance Proteins (MCM) and Cancer Prognosis: A meta-analysis.
P2860
Q28478359-8848649B-52D0-4DA6-A668-2052D833D5D6Q33690336-2B4349F0-423F-4309-A241-8E975A653537Q33739680-A0C0CE1F-D1BF-4B70-9F4B-79EA1E0111EBQ34054213-47F33CE3-DD84-4F06-A1B4-158F4FA7CFC2Q34063596-9151C298-4512-4E26-BFA5-D240CCA8561FQ34231627-85EE3C39-6229-434C-BBCB-2C2BD22885D1Q34258777-65D87344-DBAB-4DCB-88BF-F5CF1F7055B1Q34363419-6D1C02EE-E59C-441B-BD45-9D92A805149FQ34493886-2A30D185-D42D-49DC-ABD6-B8FC81990E8BQ35379924-B02B326C-CA87-4432-AB8C-1E056C89B370Q36653584-84DE5D2C-490E-454B-9F33-8529FA315DF2Q36730394-174A705F-0333-48D4-B64D-DD8C11FFEE6BQ36824730-48BF7415-7DF2-44ED-BE99-7DF1F0CD05F7Q37063510-6335904C-03D8-49FD-9810-D17CF25D7D92Q37099041-E75DDCAF-F70F-4F8F-8FEB-F5094D31D058Q37290504-966BA921-565D-48BD-BCA8-B05CD5C5BB6BQ37351498-FD95223D-DF0E-46F5-B1D5-F57FD8710D05Q37407344-BABDEFE0-60F3-4A0D-A077-A8438D8E0DDEQ37715501-719B111F-4083-4CE0-BC41-84FE2BC18438Q37740951-41AE4187-E4B2-4A21-A4C8-DC6AD3A4A301Q37921641-8174420E-EA85-469A-9AE4-4F847243CDD3Q38027568-232DD5E1-6463-46B8-BC71-55C2AF95A22EQ38708134-D1CB54E8-E2A3-48FF-8630-C0D3C33CE211Q38768444-E4185F39-7D23-40B6-AC8F-DD099390525BQ38802097-9BA3EDD3-88A9-4657-82E4-6B35B6517448Q38819850-01C418BB-7A8F-4CAE-B78D-8928F91F735EQ38822034-4DA5D042-CE97-4B0F-A323-30BB836F6A82Q39069764-16BF38DB-D4B1-4DA6-8A57-762E3022D18CQ46896445-786A0427-618D-42B5-96AD-6314BCEBC2DCQ47123343-0DE05420-D482-4DE9-8775-713A1FFF7000Q48102534-5A42C7AF-9B8A-4399-BDAF-CED9EA6623EBQ50072050-68AB881E-517D-4EFB-84DC-EFA5D095132AQ50326884-091B7A50-FBF3-480A-B694-1B81F2E59967Q52576421-CBABF1F0-1107-4152-A862-CAEEBA9D5201Q52714395-D53B6381-585D-40C7-B5CE-3A7C47CE73E7
P2860
HER2-positive breast cancer: current and future treatment strategies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
HER2-positive breast cancer: current and future treatment strategies.
@en
type
label
HER2-positive breast cancer: current and future treatment strategies.
@en
prefLabel
HER2-positive breast cancer: current and future treatment strategies.
@en
P1433
P1476
HER2-positive breast cancer: current and future treatment strategies.
@en
P2093
Ryan H Engel
Virginia G Kaklamani
P2860
P304
P356
10.2165/00003495-200767090-00006
P577
2007-01-01T00:00:00Z
P6179
1026366759